Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

ClinicalTrials.gov ID: NCT00267280

Public ClinicalTrials.gov record NCT00267280. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.

Study identification

NCT ID
NCT00267280
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
640 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2006 (Type not available)
Primary completion
Dec 2006 (Actual)
Completion
Dec 2006 (Actual)
Last update posted
Feb 17, 2012

2006

United States locations

U.S. sites
51
U.S. states
24
U.S. cities
51
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama — —
Pfizer Investigational Site Mesa Arizona — —
Pfizer Investigational Site Alhambra California — —
Pfizer Investigational Site Inglewood California — —
Pfizer Investigational Site Los Angeles California — —
Pfizer Investigational Site Santa Ana California — —
Pfizer Investigational Site Wilmington Delaware — —
Pfizer Investigational Site Fort Lauderdale Florida — —
Pfizer Investigational Site Hollywood Florida — —
Pfizer Investigational Site Jacksonville Florida — —
Pfizer Investigational Site Merritt Island Florida — —
Pfizer Investigational Site Pensacola Florida — —
Pfizer Investigational Site Vero Beach Florida — —
Pfizer Investigational Site Winter Park Florida — —
Pfizer Investigational Site Atlanta Georgia — —
Pfizer Investigational Site Conyers Georgia — —
Pfizer Investigational Site Woodstock Georgia — —
Pfizer Investigational Site Hinsdale Illinois — —
Pfizer Investigational Site La Grange Illinois — —
Pfizer Investigational Site Park Ridge Illinois — —
Pfizer Investigational Site Springfield Illinois — —
Pfizer Investigational Site Kansas City Kansas — —
Pfizer Investigational Site Lexington Kentucky — —
Pfizer Investigational Site Baltimore Maryland — —
Pfizer Investigational Site Bethesda Maryland — —
Pfizer Investigational Site Elkton Maryland — —
Pfizer Investigational Site Flint Michigan — —
Pfizer Investigational Site Springfield Missouri — —
Pfizer Investigational Site Lawrenceville New Jersey — —
Pfizer Investigational Site Albany New York — —
Pfizer Investigational Site Seaford New York — —
Pfizer Investigational Site Charlotte North Carolina — —
Pfizer Investigational Site Cincinnati Ohio — —
Pfizer Investigational Site Mansfield Ohio — —
Pfizer Investigational Site Hillsboro Oregon — —
Pfizer Investigational Site Beaver Pennsylvania — —
Pfizer Investigational Site Flourtown Pennsylvania — —
Pfizer Investigational Site Philadelphia Pennsylvania — —
Pfizer Investigational Site Yardley Pennsylvania — —
Pfizer Investigational Site Greenville South Carolina — —
Pfizer Investigational Site Collierville Tennessee — —
Pfizer Investigational Site Kingsport Tennessee — —
Pfizer Investigational Site Knoxville Tennessee — —
Pfizer Investigational Site North Richland Hills Texas — —
Pfizer Investigational Site Spring Texas — —
Pfizer Investigational Site Salt Lake City Utah — —
Pfizer Investigational Site West Jordan Utah — —
Pfizer Investigational Site Richmond Virginia — —
Pfizer Investigational Site Bellevue Washington — —
Pfizer Investigational Site Puyallup Washington — —
Pfizer Investigational Site Tacoma Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00267280, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2012 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00267280 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →